Drug Trial Radar · NCT00097695
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Dec 28, 2004
Primary completion
Jul 17, 2006
Study completion Jul 17, 2006
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 29, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).
Conditions
- Angioedema
Interventions
IcatibantDrug
30 mg (3mL) subcutaneous icatibant injection in the abdominal region
PlaceboDrug
Solution for injection, matched to study drug Single dose: 3 mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Symptom Relief (TOSR)Time frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Georgetown University Hospital, Lombardi Cancer Center
Washington D.C., District of Columbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.